GLOBAL-SAVINGS-GROUP
7.12.2022 16:40:39 CET | Business Wire | Press release
Global Savings Group (GSG) and Pepper.com (Pepper) have signed a deal to join forces, combining the world’s largest shopping community with Europe’s leading shopping recommendation and rewards company. The transaction marks the biggest deal in the industry in 2022 and creates a European Champion with a global footprint. Together, GSG and Pepper will form a multinational tech company empowering shoppers in more than 20 markets to make more confident shopping decisions. GSG and Pepper will jointly operate the world’s largest shopping community, recommendation and rewards platform connecting brands and retailers with consumers across more than 2bn purchase journeys annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006042/en/
Fabian Spielberger (CEO and Founder Pepper.com) and Gerhard Trautmann (CEO and Co-founder Global Savings Group) are about to join forces. (Photo: Business Wire)
“We are incredibly excited about this industry-disrupting deal that reinforces our leading position in Europe. Together with Pepper, we will significantly enhance our ability to empower consumers and play an even more meaningful role in their daily lives which will open a wide field of development opportunities to shape the future of our industry together. Jointly, we will create a unique, impactful and even more comprehensive portfolio of shopping solutions with huge benefits for consumers, brands, retailers and publishers alike at a scale that's just not possible anywhere else. Together, we will increase our transformative impact and boost GSG’s growth”, states Dr. Gerhard Trautmann, CEO of GSG.
“Our primary focus has always been to offer the best and broadest of money saving solutions to our communities. Our collaboration with GSG will speed up this process significantly as it empowers us to branch out more. Combined, we have more than 20 years of experience in helping people to make smarter decisions and together we will provide even better and more rewarding shopping experiences. Our loyal customers and many more to come will benefit from our combined contents and technologies”, comments Fabian Spielberger, CEO of Pepper.
GSG and Pepper are both market leaders in their fields and have expanded their solutions and services through strategic acquisitions and organic growth. After the 2018 takeover of the UK loyalty specialist Pouch, GSG acquired iGraal and Shoop, the leading French and German cashback brands in 2020 and 2021 respectively, and just recently the US-based consumer brand and domain Coupons.com. Pepper has always shared GSG’s ambition to consolidate the fast-growing market in the sector and has expanded internationally since 2014. Today, Pepper operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz. Together, GSG and Pepper will continue to develop and leverage technology to build the leading platform of shopping solutions and services to constantly drive future growth in current and new markets and verticals.
About GSG
GSG is Europe’s largest shopping rewards company with an international footprint across more than 20 markets. The company’s goal is to empower consumers to get more out of life by providing them access to best savings, cashback, deals, product inspiration, reviews and other digital shopping services. Founded in 2012 and headquartered in Munich, GSG employs more than 700 employees in 12 offices across the globe.
About Pepper
Pepper.com is the world's largest shopping community. From its headquarter in Berlin and offices in Guadalajara, London, Lyon and Winnipeg, the Pepper Media Holding operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz.de which are used by 25 million consumers per month and influences 12,000 purchase decisions per minute. The company was founded in 2014 by Fabian Spielberger and Paul Nikkel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom